ENTRY       D10595                      Drug
NAME        Asfotase alfa (USAN/INN);
            Asfotase alfa (genetical recombination) (JAN);
            Strensiq (TN)
PRODUCT     STRENSIQ (Alexion Pharmaceuticals)
FORMULA     C7108H11008N1968O2206S56 
EXACT_MASS  161023.4052
MOL_WEIGHT  161122.9611
SEQUENCE    LVPEKEKDPK YWRDQAQETL KYALELQKLN TNVAKNVIMF LGDGMGVSTV TAARILKGQL
            HHNPGEETRL EMDKFPFVAL SKTYNTNAQV PDSAGTATAY LCGVKANEGT VGVSAATERS
            RCNTTQGNEV TSILRWAKDA GKSVGIVTTT RVNHATPSAA YAHSADRDWY SDNEMPPEAL
            SQGCKDIAYQ LMHNIRDIDV IMGGGRKYMY PKNKTDVEYE SDEKARGTRL DGLDLVDTWK
            SFKPRYKHSH FIWNRTELLT LDPHNVDYLL GLFEPGDMQY ELNRNNVTDP SLSEMVVVAI
            QILRKNPKGF FLLVEGGRID HGHHEGKAKQ ALHEAVEMDR AIGQAGSLTS SEDTLTVVTA
            DHSHVFTFGG YTPRGNSIFG LAPMLSDTDK KPFTAILYGN GPGYKVVGGE RENVSMVDYA
            HNNYQAQSAV PLRHETHGGE DVAVFSKGPM AHLLHGVHEQ NYVPHVMAYA ACIGANLGHC
            APASSLKDKT HTCPPCPAPE LLGGPSVFLF PPKPKDTLMI SRTPEVTCVV VDVSHEDPEV
            KFNWYVDGVE VHNAKTKPRE EQYNSTYRVV SVLTVLHQDW LNGKEYKCKV SNKALPAPIE
            KTISKAKGQP REPQVYTLPP SREEMTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT
            TPPVLDSDGS FFLYSKLTVD KSRWQQGNVF SCSVMHEALH NHYTQKSLSL SPGKDIDDDD
            DDDDDD
            (Disulfide bridge: 122-184, 472-480, 493-493', 496-496', 528-588, 634-692, 122'-184', 472'-480', 528'-588', 634'-692')
  TYPE      Peptide
REMARK      Therapeutic category: 3959
            ATC code: A16AB13
            Product: D10595<JP/US>
EFFICACY    Enzyme replacement (akaline phosphatase)
  DISEASE   Hypophosphatasia [DS:H00213]
  TYPE      Enzyme replacement therapy product
TARGET      ALPL* [HSA_VAR:249v1] [HSA:249] [KO:K01077]
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             A ALIMENTARY TRACT AND METABOLISM
              A16 OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
               A16A OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
                A16AB Enzymes
                 A16AB13 Asfotase alfa
                  D10595  Asfotase alfa (USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Genetic, Enzyme, or Protein Disorder: Replacement, Modifiers, Treatment
              Asfotase Alfa
               D10595  Asfotase alfa (USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             3  Agents affecting metabolism
              39  Other agents affecting metabolism
               395  Enzyme preparations
                3959  Others
                 D10595  Asfotase alfa (USAN/INN); Asfotase alfa (genetical recombination) (JAN)
            Target-based classification of drugs [BR:br08310]
             Enzymes
              Hydrolases (EC3)
               Phosphatases
                ALPL* [HSA_VAR:249v1]
                 D10595  Asfotase alfa (USAN/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D10595
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D10595
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D10595
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D10595
            Pharmacogenomic biomarkers [br08341.html]
             Germline mutations in genetic disorder treatments
              D10595
DBLINKS     CAS: 1174277-80-5
            PubChem: 254741557
///
